OGA

O-GlcNAc hydrolase; O-GlcNAcase

OGA (O-GlcNAcase) is an enzyme catalyses the removal of the O-GlcNAc post-translational modification. O-GlcNAcylation is the dynamic and ubiquitous post-translational glycosylation of nucleocytoplasmic proteins on serine/threonine residues; it is implicated in regulation of the cell cycle. O-GlcNAcylation is the dynamic and ubiquitous post-translational glycosylation of nucleocytoplasmic proteins on serine/threonine residues; it is implicated in regulation of the cell cycle.

OGA Inhibitors (7)

OGA Related Products (11):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-12588

Thiamet G	Inhibitor	99.99%
Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with K_i of 20 nM for human OGA.

HY-108241

(Z)-PUGNAc		99.13%
(Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.

HY-130121

MK-8719		99.55%
MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (K_i=7.9 nM for hOGA) with excellent CNS penetration.

HY-144681

LY3372689	Inhibitor	98.74%
LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.

HY-156586

ASN90	Inhibitor	99.63%
ASN90 is a specific and orally active O-GlcNAcase (OGA) enzyme inhibitor with IC₅₀ value of 10.2 nM. ASN90 can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies.

HY-161953

O-GlcNAcase-IN-2	Inhibitor
O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC₅₀=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects.

HY-131979

TP-040		98.59%
TP-040 (O-GlcNAcase-IN-1) is a potent and novel OGA inhibitor with an IC₅₀ value of 46 nM.

HY-139431

NAG-thiazoline	Inhibitor	98.08%
NAG-thiazoline is a O-GlcNAcase inhibitor with a K_i of 180 nM. NAG-thiazoline is a potent GH20 GlcNAcase (VhGlcNAcase) inhibitor with an IC₅₀ of 11.9 μM and a K_i of 62 µM.

HY-144682

(2R,4R)-LY3372689
O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease.

HY-144681A

rel-LY3372689	Inhibitor
rel-LY3372689 is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease (WO2018140299A1; Compound Formula Ic).

HY-108246

GlcNAcstatin	Inhibitor
GlcNAcstatin is a selective glucoimidazole-based bacterial O-GlcNAcase inhibitor with a K_i of 4.6 pM. GlcNAcstatin shows 100000-fold selectivity over HexA/B.

Name
Email *

	Sorry, but the email address you supplied was invalid.